Corvus Pharmaceuticals' Soquelitinib Shows Median Progression Free Survival Of 6.2 Months And Median Overall Survival Of 28.1 Months In T-Cell Lymphoma; Supports Ongoing Phase 3 Trial

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies

Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases

Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation

Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL. The presentation highlights preclinical and clinical data supporting the development of soquelitinib in oncology and immune and inflammatory diseases, including data detailing its mechanism of action.